CN102872073A - Application of Houttuynoid C in drugs for treating ovarian cancer - Google Patents
Application of Houttuynoid C in drugs for treating ovarian cancer Download PDFInfo
- Publication number
- CN102872073A CN102872073A CN2012104170943A CN201210417094A CN102872073A CN 102872073 A CN102872073 A CN 102872073A CN 2012104170943 A CN2012104170943 A CN 2012104170943A CN 201210417094 A CN201210417094 A CN 201210417094A CN 102872073 A CN102872073 A CN 102872073A
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- ovarian cancer
- drugs
- application
- human ovarian
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses an application of Houttuynoid C in drugs for treating human ovarian cancer, belonging to the technical field of a new application of drugs. Through external MTT (Methyl Thiazolyl Tetrazolium) antineoplastic activity evaluation, the invention discovers that Houttuynoid C also has an obvious inhibition effect on the growth of human ovarian cancer strains HO-8910, HOC1 and OVAC. Thus, Houttuynoid C can be applied to preparing anti-ovarian cancer drugs and has good development and application prospects. The application of Houttuynoid C in drugs for treating human ovarian cancer disclosed by the invention is publicized for the first time; and as the skeleton type is brand new, Houttuynoid C has an unexpectedly strong inhibitory activity to human ovarian cancer cells.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid C, relate in particular to the application of Houttuynoid C in the preparation ovarian cancer resistance medicament.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound H outtuynoid C that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes of the Houttuynoid C that the present invention relates in preparation treatment ovarian cancer medicine, because framework types belongs to brand-new framework types, and its inhibition for ovarian cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously ovarian cancer obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid C in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid C in the preparation ovarian cancer resistance medicament, and the structural formula of Houttuynoid C is shown in formula I:
Formula I
The present invention finds that by external MTT anti-tumor activity evaluation Houttuynoid C also has significant inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC, suppresses the IC of this 3 strain Growth of Cells
50Value is respectively 0.29 ± 0.07 μ M, 0.36 ± 0.07 μ M and 0.19 ± 0.06 μ M.Therefore, Houttuynoid C can for the preparation of ovarian cancer resistance medicament, have good development prospect.
The purposes of the Houttuynoid C that the present invention relates in preparation treatment ovarian cancer medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for ovarian cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously ovarian cancer obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid C involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid C tablet involved in the present invention:
Get 20 and digest compound Houttuynoid C, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid C capsule involved in the present invention:
Get 20 and digest compound Houttuynoid C, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Houttuynoid C to human oophoroma cell line's growth inhibited effect
1. method: the cell that is in the growth logarithmic (log) phase: human oophoroma cell line HO-8910, HOC1 and OVAC(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid C of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Houttuynoid C has significant inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC.This chemical compound suppresses the IC of human oophoroma cell line HO-8910, HOC1 and OVAC growth
50Value is respectively: 0.29 ± 0.07 μ M, 0.36 ± 0.07 μ M and 0.19 ± 0.06 μ M.
Shown that by above-described embodiment Houttuynoid C of the present invention has good inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC.Prove that thus Houttuynoid C of the present invention has the ovarian cancer resistance activity, can be for the preparation of ovarian cancer resistance medicament.
Claims (1)
1.Houttuynoid the application of C in treatment ovarian cancer medicine, described compound H outtuynoid C-structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210417094.3A CN102872073B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in preparing drugs for treating ovarian cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210417094.3A CN102872073B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in preparing drugs for treating ovarian cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872073A true CN102872073A (en) | 2013-01-16 |
| CN102872073B CN102872073B (en) | 2014-04-16 |
Family
ID=47473744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210417094.3A Expired - Fee Related CN102872073B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in preparing drugs for treating ovarian cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872073B (en) |
-
2012
- 2012-10-27 CN CN201210417094.3A patent/CN102872073B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| SHAO-DAN CHEN等: "Houttuynoids A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata", 《ORGANIC LETTERS》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872073B (en) | 2014-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872073B (en) | Application of Houttuynoid C in preparing drugs for treating ovarian cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102872077B (en) | Application of Houttuynoid B in drugs for treating endometrial cancer | |
| CN102872075A (en) | Application of Houttuynoid E in drugs for treating breast cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN102872080B (en) | Application of Houttuynoid A in drugs for treating cervical cancer | |
| CN102872123B (en) | Application of Houttuynoid C in medicament for treating bladder cancer | |
| CN102872081B (en) | Application of Houttuynoid C in drugs for treating gastric cancer | |
| CN102872112B (en) | Application of Houttuynoid A in medicament for treating bladder cancer | |
| CN102872121B (en) | Application of Houttuynoid C in medicament for treating laryngocarcinoma | |
| CN102872070B (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer | |
| CN102861077B (en) | Application of Houttuynoid D in medicine for treating cervical cancer | |
| CN102861099A (en) | Application of Houttuynoid D in medicine for treating endometrial cancer | |
| CN102861065A (en) | Application of Houttuynoid E in medicine for treating gastric cancer | |
| CN102895247A (en) | Application of Houttuynoid B to medicament for treating oophoroma | |
| CN102861086A (en) | Application of Houttuynoid E in medicine for treating ovarian cancer | |
| CN102861046A (en) | Application of Houttuynoid A in ovarian cancer treatment medicine | |
| CN102872074A (en) | Application of Houttuynoid C in drugs for treating kidney cancer | |
| CN102872125A (en) | Application of Houttuynoid C in medicament for treating cervical cancer | |
| CN102861096A (en) | Application of Houttuynoid E in medicine for treating cervical cancer | |
| CN102872151A (en) | Application of Houttuynoid B in medicament for treating nasopharyngeal cancer | |
| CN102872137A (en) | Application of Houttuynoid B in drug for treating cervical cancer | |
| CN102872139A (en) | Application of Houttuynoid C in drug for treating tongue cancer | |
| CN102872117A (en) | Application of Houttuynoid D in medicament for treating gastric cancer | |
| CN102872102A (en) | Application of Houttuynoid C in medicine for treating breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140416 Termination date: 20151027 |
|
| EXPY | Termination of patent right or utility model |